Join Regulatory Compliance Associates® Inc. (RCA) and Nelson Labs at booth #321 during PDA Week in Denver, CO March 22 – 27, 2026. The event will be held at the Gaylord Rockies Resort & Convention Center.
Celebrating PDA’s 80th and 20th anniversaries, PDA Week 2026 brings together industry leaders and innovators from around the globe to explore the latest in pharmaceutical science, technology, and regulatory advancements. With a dynamic program filled with best practices and forward-looking insights, PDA members have a chance to deepen their professional skills and expertise.
Event Participants
Susan Schniepp, RCA’s Distinguished Fellow, has been chosen as one of this year’s PDA Industry and Honor Award winners. The ceremony will take place at PDA Week on Sunday, March 22. Sue will also be helping moderate a few of the presentations during the event as well as bring her expert perspective to the panel discussions with her 40+ years of quality consulting expertise.
Digital Twin-Driven Continuous Process Verification: Securing Data Integrity and Compliance
Monday, 23 March – 15:30 – 15:50 | Colorado Ballroom C
RCA’s Cybersecurity SME, Jason Tugman, will be apart of the discussion panel discussing how Digital Twin–Driven Continuous Process Verification (CPV) leverages virtual replicas of pharmaceutical manufacturing processes to enable real-time monitoring, control, and optimization of critical quality attributes. By integrating ALCOA+–compliant data capture and audit trails within these digital models, organizations can ensure the accuracy, integrity, and traceability of production data throughout the product lifecycle. Advanced cybersecurity frameworks safeguard the twin ecosystem—protecting against unauthorized access, data breaches, and ransomware threats—while supporting FDA 21 CFR Part 11 and ICH Q13 regulatory requirements. This presentation will outline the technological architecture of digital twins in GMP environments, demonstrate how CPV accelerates batch release and inspection readiness, and provide a practical roadmap for implementing a secure, compliant digital twin infrastructure that transforms traditional quality systems into proactive, data-driven operations.
IG5: Drug Compounding
Tuesday, 24 March – 14:00 – 15:00 | Colorado Ballroom D
RCA’s Global Head of Operations, Arie Anahory, will be co-leading and working alongside PDA in the 503B Compounding Interest Group. The group intends to bring together industry leaders involved in pharmaceutical compounding operating under Sections 503A and 503B of the FD&C Act. The group will focus on fostering collaboration and dialogue surrounding discussions on emerging regulations, best practices, and navigating the landscape of compliance. Topics covered will include production techniques, personnel practices, facility management, control of materials, and application of GMPs in daily operations ensuring quality for all drug products.
